{"id":"W2483350877","doi":"10.1182/blood.v126.23.1742.1742","title":"A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada); CancerCare Manitoba; Princess Margaret Cancer Centre","funders":"","keywords":"Ofatumumab; Medicine; Fludarabine; Internal medicine; Chronic lymphocytic leukemia; Refractory (planetary science); Regimen; Gastroenterology; Neutropenia; Phases of clinical research; Pharmacodynamics; Oncology; Pharmacology; Pharmacokinetics; Leukemia; Clinical trial; Cyclophosphamide; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004555819,0.0003289609,0.0007480561,0.0005800414,0.00002882794,0.0000251531,0.0002344536,0.0001419824,0.00001442937],"category_scores_gemma":[0.0002485657,0.0002389287,0.00003968096,0.001424805,0.0001397777,0.0002072705,0.0001041553,0.0003052447,0.00001263597],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.05038923,"about_ca_system_score_gemma":0.02619909,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01108365,"about_ca_topic_score_gemma":0.007075651,"domain_scores_codex":[0.9965986,0.000207298,0.0006622943,0.00057038,0.001333906,0.0006275112],"domain_scores_gemma":[0.9982924,0.00009783165,0.0002151625,0.0006927547,0.000430181,0.0002716285],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.04180794,0.1114536,0.8101943,0.001686154,0.0009977677,0.003893659,0.01946571,0.001123502,0.001214696,0.00002335577,0.0002812574,0.007858033],"study_design_scores_gemma":[0.8898689,0.04786257,0.04653273,0.001336634,0.0003650673,0.00009807369,0.0009702318,0.006216067,0.006364945,0.00001152056,0.00002131096,0.0003519434],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953349,0.000324929,0.000002650996,0.00001306045,0.00002398143,0.003951951,0.000006434082,0.00005827488,0.0002837665],"genre_scores_gemma":[0.9992603,0.00001065446,0.0000562795,0.00001545893,0.00003832966,0.0003213602,0.0000814115,0.00006786983,0.0001483193],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.848061,"threshold_uncertainty_score":0.9955016,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01830524461602995,"score_gpt":0.28747154493414,"score_spread":0.2691663003181101,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}